Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomised Controlled Crossover Trial

Nina-Francesca Parrella, Aron T Hill, Peter G Enticott, Tanita Botha, Sarah Catchlove, Luke Downey, Talitha C Ford
{"title":"Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomised Controlled Crossover Trial","authors":"Nina-Francesca Parrella, Aron T Hill, Peter G Enticott, Tanita Botha, Sarah Catchlove, Luke Downey, Talitha C Ford","doi":"10.1101/2024.06.19.24309024","DOIUrl":null,"url":null,"abstract":"Cannabidiol (CBD), a non-intoxicating compound derived from the cannabis plant, has garnered increasing attention as a potential pharmacological therapeutic for autistic children. We conducted a randomised double-blind, placebo-controlled, crossover trial to understand whether oral CBD oil can improve behaviours in this population, with a primary focus on social relating outcomes, along with anxiety and parental stress. A total of 29 children (18 male), aged 5 to 12 years (M = 9.62 years, SD = 2.05), diagnosed with autism spectrum disorder, completed the study. Participants received weight-based dosing of CBD oil (10 mg/kg/day) or placebo oil over two 12-week intervention periods (crossover), separated by an 8-week washout period. Outcome measures included the Social Responsiveness Scale-2 (SRS-2; primary outcome), PROMIS Social Relating, Anxiety, and Sleep, Developmental Behaviour Checklist-2 (DBC-2), Vineland 3, and Autism Parenting Stress Index (APSI; secondary outcomes). There was no significant effect observed for the primary outcome measure (SRS-2) for CBD oil relative to placebo oil after 12 weeks, (p=.125). Significant improvements were observed in secondary measures of social functioning (PROMIS-Social, DBC-2 Social Relating; p<.05) and anxiety symptoms (PROMIS Anxiety, DBC-2 Anxiety; p<.05), while there was also a reduction in parental stress (p<.05). Safety and tolerability data indicated that two children experienced gastrointestinal discomfort while taking CBD. This pilot trial represents preliminary evidence for the potential therapeutic effects of CBD in autism. While further research is needed to confirm and extend these findings, the results suggest that CBD may be a promising intervention for addressing one of autism's core symptoms: social relating. Future studies with larger sample sizes are needed to fully evaluate the efficacy and safety of CBD for autistic children.","PeriodicalId":501447,"journal":{"name":"medRxiv - Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.06.19.24309024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cannabidiol (CBD), a non-intoxicating compound derived from the cannabis plant, has garnered increasing attention as a potential pharmacological therapeutic for autistic children. We conducted a randomised double-blind, placebo-controlled, crossover trial to understand whether oral CBD oil can improve behaviours in this population, with a primary focus on social relating outcomes, along with anxiety and parental stress. A total of 29 children (18 male), aged 5 to 12 years (M = 9.62 years, SD = 2.05), diagnosed with autism spectrum disorder, completed the study. Participants received weight-based dosing of CBD oil (10 mg/kg/day) or placebo oil over two 12-week intervention periods (crossover), separated by an 8-week washout period. Outcome measures included the Social Responsiveness Scale-2 (SRS-2; primary outcome), PROMIS Social Relating, Anxiety, and Sleep, Developmental Behaviour Checklist-2 (DBC-2), Vineland 3, and Autism Parenting Stress Index (APSI; secondary outcomes). There was no significant effect observed for the primary outcome measure (SRS-2) for CBD oil relative to placebo oil after 12 weeks, (p=.125). Significant improvements were observed in secondary measures of social functioning (PROMIS-Social, DBC-2 Social Relating; p<.05) and anxiety symptoms (PROMIS Anxiety, DBC-2 Anxiety; p<.05), while there was also a reduction in parental stress (p<.05). Safety and tolerability data indicated that two children experienced gastrointestinal discomfort while taking CBD. This pilot trial represents preliminary evidence for the potential therapeutic effects of CBD in autism. While further research is needed to confirm and extend these findings, the results suggest that CBD may be a promising intervention for addressing one of autism's core symptoms: social relating. Future studies with larger sample sizes are needed to fully evaluate the efficacy and safety of CBD for autistic children.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
大麻二酚对自闭症儿童社交关系、焦虑和父母压力的影响:随机对照交叉试验
大麻二酚(CBD)是一种从大麻植物中提取的无毒化合物,作为一种潜在的自闭症儿童药物疗法,它已引起越来越多的关注。我们进行了一项随机双盲、安慰剂对照、交叉试验,以了解口服 CBD 油是否能改善自闭症儿童的行为,主要关注点是社交相关结果、焦虑和父母压力。共有 29 名被诊断患有自闭症谱系障碍的 5 至 12 岁儿童(18 名男性)(中位数 = 9.62 岁,标准差 = 2.05)完成了这项研究。在两个为期 12 周的干预期(交叉)中,参与者按体重服用 CBD 油(10 毫克/千克/天)或安慰剂油,中间有 8 周的冲洗期。结果测量包括社会反应性量表-2(SRS-2;主要结果)、PROMIS社交关系、焦虑和睡眠、发育行为核对表-2(DBC-2)、文兰3和自闭症养育压力指数(APSI;次要结果)。与安慰剂油相比,12周后,在主要结果测量(SRS-2)方面,没有观察到CBD油有明显效果(p=0.125)。在社会功能(PROMIS-Social、DBC-2 Social Relating;p<.05)和焦虑症状(PROMIS Anxiety、DBC-2 Anxiety;p<.05)的次要测量中观察到了显著改善,同时父母的压力也有所减轻(p<.05)。安全性和耐受性数据表明,两名儿童在服用 CBD 时出现了肠胃不适。这项试点试验初步证明了 CBD 对自闭症的潜在治疗效果。虽然还需要进一步的研究来证实和扩展这些发现,但研究结果表明,对于自闭症的核心症状之一--社交关系,CBD 可能是一种很有前景的干预措施。未来需要进行样本量更大的研究,以全面评估 CBD 对自闭症儿童的疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Tucaresol: An Oral Candidate Drug With Two Distinct Antiviral Mechanisms. Comparative Risk of the Onset of Atrial Fibrillation after Icosapent Ethyl versus Omega-3–Acid-Ethyl-Esters Adjuvant to Statins A Novel Maxillofacial Technology for Drug Administration-A Randomized Controlled Trial Using Metronidazole. Protective Effects of Psychiatric Medications against COVID-19 Mortality Before Vaccines Anti-cancer effect of memantine as adjunctive therapy in metastatic colon cancer: A pilot randomized controlled clinical trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1